Matthew Nelson

📢 News: Sonrai Accelerates Cancer Therapeutics Research with Advanced Analytics 📰 Read now: https://lnkd.in/dPMqy8D2 Sonrai’s AI data management and analysis technology will enable the Henri & Belinda Termeer Center for Targeted Therapies at Massachusetts General Hospital to manage vast multi-omic and multi-modal data to accelerate oncological research into personalized therapies using advanced analytics. 👋 To discuss how we can help advance your therapeutics development, book a chat with us: https://lnkd.in/dEnkdQdV #precisionmedicine #oncology #AI #dataanalytics #Sonrai #SonraiDiscovery #drugdevelopment #immunooncology #biomarkerdiscovery

32

The Drug Discovery Biology & Bioinformatics Strategy Meeting East Coast on May 14th brings Gregory Williams, Curia's Senior Research Scientist II, to Princeton. Prepare to explore how emerging technologies and platforms can be harnessed to unlock a broader target space for drug discovery. Dr. Williams will also delve into strategies for efficiently validating promising targets and ensuring their therapeutic potential. We'll explore the crucial role of target specificity and selectivity in the drug discovery process, along with the methods used to assess these factors. The session will unveil the power of computational modeling and artificial intelligence in identifying novel drug targets and predicting hit efficacy. Dr. Williams will address the challenges of target identification in complex diseases with multiple pathways and targets. He'll also discuss strategies for overcoming target redundancy and prioritizing those with the highest therapeutic potential. Currently leading Curia's Cell-Based Assay Technologies team, Dr. Williams is a key player in driving innovative pre-clinical drug discovery programs. This session promises to be a goldmine of insights for anyone navigating the complexities of target identification. Stay tuned for more! #ClinicalTrials #DrugDiscovery #TargetIdentification #EastCoastScience #GregWilliams #CBAT #StrategyMeeting

1

Join HealthVerity and Quest on June 12 at 12:00 p.m. ET as we explore the breadth and scope of biomarker data readily available in HealthVerity Marketplace and discuss the variety of use cases for this powerful data type, including physician alerts to optimize provider education and outreach https://hubs.ly/Q02zlXGq0

4

Embracing “Worst-Case Studies” for Upstream Development A biotech company working on cancer immunotherapies has adopted a novel tool for designing experiments, which it hopes will support future data-driven decision making. Wilhad H. Reuter, lead engineer for upstream process development at Mural Oncology, and his team adopted a Design of Experiment (DoE) approach for their studies into worst-case scenarios for upstream processes. According to Reuter, taking a cue from DoE to worst-case studies is unique for smaller companies. By relying on JMP statistical software, Reuter’s team identified three parameters (pH, temperature, and initial cell seeding density) that predicted cell culture performance. https://lnkd.in/gzjTsDDc #aspenalert #biotech #bioprocess

9

Life Sciences DNA podcast, episode 11. Dimitrios Skaltsas CEO and co-founder of Intelligencia AI, sits down with Amar Drawid, Ph.D. to discuss how AI can support data-driven decision-making in drug development, improve the probability for success in clinical trials, and de-risk clinical development. Watch now - https://lnkd.in/g5t-PFW8 #AI #drugdevelopment #decisionmaking

10

1 Comment

Veronica Venafra now at #BITS2024. This presentation will explore how SignalingProfiler integrates multi-omics data to identify phenotypic hallmarks, facilitating new approaches in drug repurposing. #Bioinformatics #MultiOmics #DrugRepurposing 

10

Hear from Michael Severino, Flagship CEO-Partner & CEO of #FlagshipFounded Tessera Therapeutics, on his career journey to Tessera and and how the company is pioneering Gene Writing™, a new genome engineering technology that writes therapeutic messages into the genome to treat diseases at their source in this Inside Precision Medicine podcast episode with Jonathan D. Grinstein, PhD: https://lnkd.in/dsNDM3qY

14

#CZBiohubSF is “computational biologists’ heaven,” says Yasin Şenbabaoğlu, Biohub SF’s new Director of Computational Biology. That’s because “Biohub researchers are generating unique, large datasets that aren’t being prioritized by industry or academia.” Şenbabaoğlu brings to his new role a wealth of experience in cancer immunology and genomics as well as the development of multimodal AI tools for biological discovery. Read about his journey and his vision for future projects: https://lnkd.in/ggjaWR-x #computationalbiology #datascience #genomics #cancer #AI

247

7 Comments

NPC's - #LLM and Chronicling a realm where input signals aren't confined to customary data sources but diffused across disparate computational dimensions, super prompts are conferred dominion over a maelstrom of #information – encompassing both structured datasets and amorphous text corpora. This multidimensional panorama bestows upon them the capacity to harmonize an eclectic assortment of #data, affording outputs that are both recondite in their #wisdom and highly pertinent to their respective contexts.

3

How do we use Groovy when writing #Nextflow #Bioinformatics pipelines? Senior #Bioinformatics Engineer Jason Fan recently gave an insightful talk at the Boston 2024 #Nexflow Summit. Titled: "Get into the Groovy: using Groovy to model sample sheets, input and metadata, and more", this talk is a must-see for anyone interested in #Genomics and #Bioinformatics. Check out the video here: https://lnkd.in/gxNcFcHr

16

Editas Medicine and Genevant Sciences team up in $238 million deal to develop an in vivo genome editing strategy. Read more about the pivot in our latest article from Nnenna Ohaka: https://lnkd.in/esrajWUB

1

Don’t miss the latest episode of The Bio Report podcast, where our CBO Hilary Eaton, PhD joined Daniel Levine for a wide-ranging conversation about the role of #GenerativeAI in drug development, our OpenCRISPR-1 molecule and why we made it open-source. 👉 https://lnkd.in/gkD4iAEt #AI #CRISPR #OpenCRISPR #ProteinDesign #Podcast

20

Our founder and CEO Jen Nwankwo, Ph.D. sat with Genetic Engineering & Biotechnology News to discuss our differentiated multimodal data strategy, which integrates computational data, wet lab proxy biological data, and wet lab ground truth biological data to overcome the low data regime problem that has historically limited the application of state-of-the-art foundational models in the pharmaceutical industry.    To advance small and large molecule drug discovery, we employ a multimodal AI platform powered by laboratory automation. Our platform’s name—Input, Transform, Output (ITO)—reflects our company’s comprehensive approach, spanning proprietary data generation, data orchestration, AI, and high throughput laboratory automation in iterative training and testing loops.    To gain access to our ITO platform, click here: https://lnkd.in/ek9dbk3T  Read the full GEN feature: https://lnkd.in/gynQxCjF   

46

You're cordially invited to join as an audience member for an Exclusive Panel Discussion on the Future of Drug Development with AI/ML! You can RSVP here: https://lnkd.in/eExr_mFN Esteemed colleagues in the life sciences field, it is with great pleasure that we extend this formal invitation to a thought-provoking exploration of the convergence of artificial intelligence and machine learning in drug development. Our distinguished panel comprises 4 leading executives from the life sciences industry, complemented by 2 accomplished moderators. Together, they will navigate the transformative impact of AI/ML on the future of drug discovery, development, and deployment. While these advancements reverberate globally, our discussion will spotlight the unique implications for the vibrant life sciences sector in North Carolina and the esteemed Research Triangle area.  Kindly Mark Your Calendar:  Wednesday, July 17, 2024  9:00am-9:50am ET USA The Zoom link will be provided closer to the event date. In case of scheduling conflicts, rest assured, the session will be recorded and made available for later viewing. Please extend this invitation to your esteemed peers, and let us convene to ignite a conversation that will shape the future of life sciences together! #AI #ML #DrugDevelopment #LifeSciences #NorthCarolina #ResearchTriangle #Innovation

6

Join Director of Computational Biology, Basel A. at NextGen Omics. Basel will be presenting Granular Multiomics To Identify Affected Genes From Non-coding Genetics in Conference Room 2 on Day 2 (24/10) at 12:05. https://lnkd.in/gjxejFiD ABSTRACT: It is estimated that 90% of disease causing variants are non-coding. Here we present a multiomics approach, utilising machine learning, genomics, 3D genomics, epigenomics, and transcriptomics, to identify candidate functional non-coding variants, and thereafter to resolve the mechanism through which they perturb gene regulation. #ML #genomics #multiomics

21